Difference between revisions of "HepPar-1"
Jump to navigation
Jump to search
(Created page with "'''HepPar-1''' is an commonly used immunostain. ==Positive== *Hepatocellular carcinoma - 18/19 cases.<ref>{{Cite journal | last1 = Fan | first1 = Z. | last2 = van de...") |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
==Positive== | ==Positive== | ||
*[[Hepatocellular carcinoma]] - 18/19 cases.<ref>{{Cite journal | last1 = Fan | first1 = Z. | last2 = van de Rijn | first2 = M. | last3 = Montgomery | first3 = K. | last4 = Rouse | first4 = RV. | title = Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. | journal = Mod Pathol | volume = 16 | issue = 2 | pages = 137-44 | month = Feb | year = 2003 | doi = 10.1097/01.MP.0000052103.13730.20 | PMID = 12591966 }}</ref> | *[[Hepatocellular carcinoma]] - 18/19 cases.<ref>{{Cite journal | last1 = Fan | first1 = Z. | last2 = van de Rijn | first2 = M. | last3 = Montgomery | first3 = K. | last4 = Rouse | first4 = RV. | title = Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. | journal = Mod Pathol | volume = 16 | issue = 2 | pages = 137-44 | month = Feb | year = 2003 | doi = 10.1097/01.MP.0000052103.13730.20 | PMID = 12591966 }}</ref> | ||
===Occasionally positive=== | |||
*[[Gastric adenocarcinoma]]. | |||
*[[Lung adenocarcinoma]] - especially [[SMARCA4-deficient non-small cell carcinoma of the lung]].<ref name=pmid28555282>{{Cite journal | last1 = Agaimy | first1 = A. | last2 = Fuchs | first2 = F. | last3 = Moskalev | first3 = EA. | last4 = Sirbu | first4 = H. | last5 = Hartmann | first5 = A. | last6 = Haller | first6 = F. | title = SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1 | journal = Virchows Arch | volume = 471 | issue = 5 | pages = 599-609 | month = Nov | year = 2017 | doi = 10.1007/s00428-017-2148-5 | PMID = 28555282 }}</ref> | |||
==See also== | |||
*[[Hepatocellular carcinoma]]. | |||
*[[Liver metastasis]]. | |||
*[[Immunohistochemistry]]. | |||
==References== | ==References== | ||
{{ | {{Reflist|1}} | ||
[[Category:Immunohistochemistry]] | [[Category:Immunohistochemistry]] | ||
Latest revision as of 16:22, 22 November 2019
HepPar-1 is an commonly used immunostain.
Positive
- Hepatocellular carcinoma - 18/19 cases.[1]
Occasionally positive
- Gastric adenocarcinoma.
- Lung adenocarcinoma - especially SMARCA4-deficient non-small cell carcinoma of the lung.[2]
See also
References
- ↑ Fan, Z.; van de Rijn, M.; Montgomery, K.; Rouse, RV. (Feb 2003). "Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections.". Mod Pathol 16 (2): 137-44. doi:10.1097/01.MP.0000052103.13730.20. PMID 12591966.
- ↑ Agaimy, A.; Fuchs, F.; Moskalev, EA.; Sirbu, H.; Hartmann, A.; Haller, F. (Nov 2017). "SMARCA4-deficient pulmonary adenocarcinoma: clinicopathological, immunohistochemical, and molecular characteristics of a novel aggressive neoplasm with a consistent TTF1". Virchows Arch 471 (5): 599-609. doi:10.1007/s00428-017-2148-5. PMID 28555282.